Refine
Has Fulltext
- yes (4)
Is part of the Bibliography
- yes (4)
Document Type
- Journal article (3)
- Doctoral Thesis (1)
Language
- English (4)
Keywords
- neurodegeneration (3)
- neuroinflammation (3)
- Parkinson’s disease (2)
- T cells (2)
- microglia (2)
- Channelrhodopsin (1)
- Channelrhodopsin-2 (1)
- Drosophila melanogaster (1)
- Electrophysiology (1)
- Elektrophysiologie (1)
- MCC950 (1)
- NLRP3 (1)
- Optogenetik (1)
- Parkinson's disease (1)
- Taufliege (1)
- animal models (1)
- dopaminergic cells (1)
- inflammasome (1)
- inflammatory cascades (1)
- movement disorder (1)
- optogenetics (1)
Institute
EU-Project number / Contract (GA) number
- 825575 (1)
Neuroinflammation has been suggested as a pathogenetic mechanism contributing to Parkinson’s disease (PD). However, anti-inflammatory treatment strategies have not yet been established as a therapeutic option for PD patients. We have used a human α-synuclein mouse model of progressive PD to examine the anti-inflammatory and neuroprotective effects of inflammasome inhibition on dopaminergic (DA) neurons in the substantia nigra (SN). As the NLRP3 (NOD-, LRR- and pyrin domain-containing 3)-inflammasome is a core interface for both adaptive and innate inflammation and is also highly druggable, we investigated the implications of its inhibition. Repeat administration of MCC950, an inhibitor of NLRP3, in a PD model with ongoing pathology reduced CD4\(^+\) and CD8\(^+\) T cell infiltration into the SN. Furthermore, the anti-inflammasome treatment mitigated microglial activation and modified the aggregation of α-synuclein protein in DA neurons. MCC950-treated mice showed significantly less neurodegeneration of DA neurons and a reduction in PD-related motor behavior. In summary, early inflammasome inhibition can reduce neuroinflammation and prevent DA cell death in an α-synuclein mouse model for progressive PD.